Intellia Therapeutics, Inc. (NTLA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.64: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 37%; Elevated put/call ratio: 6.83; Below-average business quality.
Intellia Therapeutics is a clinical-stage biopharmaceutical company developing CRISPR gene editing therapies, with two lead programs in Phase 3: lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis. Revenue comes from collaborations, primarily with Regeneron. The... Read more
Sell if holding. Engine safety override at $13.64: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 37%; Elevated put/call ratio: 6.83; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinenex-z (NTLA-2001)10-K Item 1A: 'we cannot predict when we will resume the MAGNITUDE Phase 3 clinical trial for nex-z, and there is a risk that we may not be able to resume the trial at all'
- HIGHpipelinelonvo-z (NTLA-2002)10-K Item 1A: 'clinical trials for nex-z (pending resolution of the clinical hold on the IND for the MAGNITUDE clinical trial) and for lonvo-z'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 9.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.64: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 37%; Elevated put/call ratio: 6.83; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $12.70. Score 5.2/10, moderate confidence.
Take-profit target: $24.17 (+77.0% upside). Prior stop was $12.70. Stop-loss: $12.70.
Concentration risk — Pipeline: nex-z (NTLA-2001); Concentration risk — Pipeline: lonvo-z (NTLA-2002); Quality below floor (2.2 < 4.0).
Intellia Therapeutics, Inc. trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
30 analysts cover NTLA with a consensus score of 3.7/5. Average price target: $27.
What does Intellia Therapeutics, Inc. do?Intellia Therapeutics is a clinical-stage biopharmaceutical company developing CRISPR gene editing therapies, with two...
Intellia Therapeutics is a clinical-stage biopharmaceutical company developing CRISPR gene editing therapies, with two lead programs in Phase 3: lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis. Revenue comes from collaborations, primarily with Regeneron. The company is preparing for a potential commercial launch of lonvo-z in the first half of 2027.